Allergan to Request Court Block Valeant and Pershing Square from Voting Shares Acquired in Violation of Insider Trading LawsAugust 27, 2014 8:27 am | News | Comments
Allergan has asked the United States District Court for the Central District of California to set an expedited schedule for discovery and a motion for a preliminary injunction against Valeant Pharmaceuticals, Pershing Square Capital Management, L.P., and its principal, William A. Ackman, for violations of the federal securities laws.
Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most...
Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical's® lead...
Valeant Pharmaceuticals International announced that the company has received a request...
Allergan Inc.'s lawsuit, filed Friday in U.S. District Court in Santa Ana, California, names as plaintiffs drugmaker Valeant Pharmaceuticals International Inc., New York investment and hedge fund firm Pershing Square Capital Management LP and its principal, William Ackerman.
Allergan announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX ® (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema.
Allergan, Inc. announced operating results for the quarter ended June 30, 2014 and announced a restructuring that will eliminate 1500 jobs.
Valeant Pharmaceuticals International Inc. is complaining to regulators that Botox maker and acquisition target Allergan has been making false statements about its business.
Pershing Square Capital Management has formally asked Allergan shareholders to support its bid for a special meeting to remove six directors and allow Valeant to proceed with its hostile takeover bid.
Pershing Square, the investment firm run by activist investor Bill Ackman, said Friday it settled a lawsuit with Allergan, the maker of Botox, related to Allergan's poison pill plan and Pershing's $53 billion offer for the company.
Allergan, announced that its Board of Directors, after consultation with its independent financial and legal advisors, unanimously determined that Valeant Pharmaceuticals International, Inc.’s unsolicited exchange offer to acquire all outstanding common shares of Allergan is grossly inadequate.
Bill Ackman's Pershing Square Capital Management, seeking legal cover in its $53 billion takeover bid for Allergan, filed a lawsuit to confirm that its push for a special meeting of shareholders won't trigger a defensive "poison pill" plan from the Botox maker.
Valeant Pharmaceuticals aims to take its bid for Allergan to the Botox maker's shareholders after Allegan's board unanimously rejected its latest offer of about $53 billion. Valeant said Tuesday that it looked forward to giving shareholders the opportunity "to speak for themselves" after Allergan Chairman and CEO David Pyott said that the offer wasn't worth discussing in a letter to his Valeant counterpart, Michael Pearson.
Allergan announced that its Board of Directors has unanimously determined that the revised unsolicited proposal from Valeant Pharmaceuticals substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the company and its stockholders.
The Newsweek Green Rankings evaluate the world's largest publicly traded companies using eight metrics that collectively provide a transparent measurement of overall corporate environmental performance. Companies were scored on each metric against their industry peers using a 0-100% scale.
Activist investor Bill Ackman said Monday that he will move to replace most of Allergan's board of directors as part of a continuing battle for control of the company.
Valeant Pharmaceuticals is sweetening its offer to buy Botox maker Allergan for the second time this week. The Canadian drugmaker said Friday it is now offering $72 and a portion of its stock for each Allergan share.
Valeant Pharmaceuticals is adding more cash to its offer to buy Botox maker Allergan in a bid that could now be worth more than $49 billion. The Canadian drugmaker says it will now offer $58.30 and a portion of its stock for each Allergan share.
Valeant Pharmaceuticals International says it will improve its bid of almost $47 billion for Botox-maker Allergan after the company rejected its hostile takeover offer. Valeant CEO Michael Pearson says the company is prepared to pay a fair price, but will remain financially disciplined when it makes its new offer later this month.
Allergan spurned a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited offer worth nearly $46 billion undervalues the company and carries significant risk.
Botox maker Allergan raised its outlook for the year Wednesday after topping expectations for the first quarter. Executives did not discuss a $45.6 billion offer last month from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman to buy the company, but did reiterate that that the proposal is under review.
Valeant Pharmaceuticals International could be pushed to increase the cash component of its bid for Botox maker Allergan by up to 40 per cent, an industry analyst said Monday.
Valeant Pharmaceuticals International says three of its directors will not stand for re-election this year as it pursues the acquisition of Botox maker Allergan, which has adopted a "poison pill" defense while it considers the offer.
WSJ discusses the Ackman/Valeant deal for Allergan.
Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.
Valeant said Monday that it intends to propose a merger with Allergan using a combination of Valeant stock and cash. The transaction size has not been disclosed, but Valeant expects the cash portion of the deal to be at least $15 billion.
Allergan reported better-than-expected earnings Wednesday and announced it is selling its Lap-Band gastric bypass business. Apollo Endosurgery will give Allergan an upfront payment of $75 million in cash plus a $15 million stake in the company in return for rights to the device, which is a stomach-restricting band used to treat obesity.
U.S. government regulators for the first time have approved Botox injections to treat crow's feet. The Food and Drug Administration said Wednesday that Allergan's Botox Cosmetic injection is the first drug approved to treat the wrinkles that form on the outside edge of the eyes. Allergan studied...
Shares of Allergan rebounded slightly Tuesday, a day after dropping by double digits on news that a generic version of one of its key drugs might face an easier-than-expected path for getting regulatory approval. The FDA said Friday that a generic version of Restasis could be accepted for approval without a requirement for testing in humans, essentially if the drug's composition is similar enough to Allergan's Restasis eye treatment.
- Page 1